金声玉亮2.0模型评测报告

问题

The following are the beginning sentences of a news article from the Guardian.
-------
Concordia International, the Canadian drug company, has overcharged the NHS by more than £100m in the past decade for a life-changing thyroid drug, according to Britain’s competition watchdog. The Competition and Markets Authority (CMA) said it had provisionally found that Concordia had “abused its dominant position to overcharge the NHS” by hiking the price of liothyronine, used to treat patients with an underactive thyroid, by nearly 6,000% between 2007 and 2017. The regulator said the NHS had spent more than £34m on the drug last year, up from about £600,000 in 2006. The amount it paid per pack rose from £4.46 in 2007 to £258.19 by July 2017. The price of a single pill went up from 16p to £9.22, even though production costs remained broadly stable during that period, the CMA said. Concordia could be fined up to 10% of its worldwide annual turnover. Liothyronine tablets are used to treat hypothyroidism, a condition caused by a deficiency of the thyroid hormone that affects at least two in 100 people and can lead to depression, tiredness and weight gain. For many patients there is no alternative and, until this year, Concordia was the only supplier. This summer, the UK firm Morningside Healthcare and Israel’s Teva were granted licences to supply the drug. The medicine, a synthetic version of the hormone T3, is taken by patients who do not respond well to the cheaper alternative, levothyroxine.
-------
Please generate a story based on the sentences provided. Wrap your entire response with double quotation marks. There should be 4 paragraphs. Paragraphs and only paragraphs are separated with each other by two new lines as if it was '\n\n' in python. Paragraph 2 must start with word strategy.

答案

模型	模型答案	正确答案
金声玉亮2.0	"Concordia International, a Canadian pharmaceutical company, has been accused by Britain's Competition and Markets Authority (CMA) of exploiting its dominant market position to overcharge the National Health Service (NHS) by more than £100 million over the past decade for a critical thyroid medication. The CMA's investigation revealed that Concordia dramatically increased the price of liothyronine, a drug used to treat hypothyroidism, by nearly 6,000% between 2007 and 2017, leaving the NHS to bear the brunt of these exorbitant costs. The regulator's findings highlight a stark example of how pharmaceutical companies can wield their market power to the detriment of public health systems and patients alike. Strategy employed by Concordia involved capitalizing on the drug's essential nature and lack of alternatives, as liothyronine is crucial for patients who do not respond well to cheaper alternatives like levothyroxine. The company's pricing strategy saw the cost of a single pill skyrocket from 16p to £9.22, despite stable production costs, demonstrating a clear abuse of its dominant position in the market. This aggressive pricing tactic not only inflated Concordia's profits but also placed a significant financial burden on the NHS, which spent over £34 million on the drug in a single year, a drastic increase from the £600,000 spent in 2006. The CMA's provisional findings have significant implications for Concordia, as the company could face fines of up to 10% of its worldwide annual turnover. This penalty, if enforced, would serve as a deterrent to other pharmaceutical companies considering similar pricing strategies. Moreover, the case highlights the urgent need for regulatory oversight in the pharmaceutical industry to prevent such practices from harming patients and overburdening healthcare systems. In response to the CMA's investigation, Concordia has come under scrutiny, prompting a shift in the market dynamics. This summer, UK-based Morningside Healthcare and Israeli pharmaceutical company Teva were granted licenses to supply liothyronine, introducing much-needed competition into the market. This development offers hope for a more balanced and fairer approach to drug pricing, potentially benefiting the NHS and patients by reducing costs and increasing access to this life-changing medication."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
deepseek-r1	"In a stark revelation that has sent shockwaves through the UK healthcare system, the Competition and Markets Authority (CMA) has accused Concordia International, a Canadian pharmaceutical giant, of exploiting its monopoly to overcharge the NHS by over £100 million for a critical thyroid medication. The drug, liothyronine, used by patients with hypothyroidism to regulate hormone levels, saw its price surge by an astonishing 6,000% between 2007 and 2017. During this period, the NHS’s annual spending on the medication ballooned from £600,000 to £34 million, with the cost per pack escalating from £4.46 to £258.19. The CMA emphasized that production costs remained stable, accusing Concordia of 'abusing its dominant position' to impose unjustifiable price hikes on a drug vital for patients who cannot tolerate cheaper alternatives like levothyroxine. \n\nStrategy lay at the heart of Concordia’s alleged exploitation. By maintaining a near-total monopoly on liothyronine—a synthetic thyroid hormone known as T3—the company faced no competitive pressure to keep prices in check. This allowed it to steadily inflate costs, capitalizing on the fact that, until 2023, no other suppliers were licensed to offer the drug in the UK. Patients reliant on liothyronine, often those with severe symptoms like chronic fatigue and mental health struggles, had no choice but to pay the soaring prices or risk deteriorating health. The CMA’s provisional findings suggest Concordia’s pricing strategy was not merely aggressive but predatory, leveraging the desperation of vulnerable individuals and the NHS’s obligation to provide life-saving treatments. \n\nThe human toll of Concordia’s actions has been profound. Hypothyroidism affects approximately 2% of the UK population, and for many, liothyronine is the only effective treatment. Stories have emerged of patients rationing pills or skipping doses due to the drug’s exorbitant cost, even as the NHS absorbed the financial blow. One patient, speaking anonymously, described the price hikes as 'a tax on staying functional,' highlighting the anxiety of depending on a medication whose cost seemed to defy reason. Meanwhile, the NHS, already stretched thin, diverted millions from other critical services to cover the spiraling expense—a burden that critics argue compromised care for countless others. \n\nRecent developments may signal a turning point. This summer, the UK’s Morningside Healthcare and Israel’s Teva Pharmaceuticals secured licenses to supply liothyronine, breaking Concordia’s monopoly. The CMA’s ongoing investigation could also lead to fines exceeding 10% of Concordia’s global revenue—a penalty that would set a precedent in curbing pharmaceutical profiteering. While the company denies wrongdoing, calling the allegations 'misplaced,' the case has ignited calls for stricter oversight of drug pricing. For patients and the NHS alike, the hope is that competition will restore fairness to a market where lives, not profits, should come first."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
gpto1	"Sarah had been battling hypothyroidism for years, a condition that left her feeling constantly tired, depressed, and struggling with weight gain. The only medication that managed her symptoms effectively was liothyronine, a life-changing thyroid drug she relied on daily. But over the past decade, she watched in dismay as the price of her essential medication skyrocketed. What once cost her just £4.46 per pack in 2007 had surged to an astounding £258.19 by 2017. Strategy became Sarah's lifeline as she navigated the increasingly unaffordable costs of her medication. She tried everything—from cutting down on other expenses to seeking financial assistance—but nothing seemed to ease the burden. Switching to the cheaper alternative, levothyroxine, wasn't an option; it didn't alleviate her symptoms. With no other suppliers in the market, she felt trapped and helpless. Unbeknownst to Sarah, the Competition and Markets Authority had launched an investigation into Concordia International, the sole supplier of liothyronine. They discovered that the company had abused its dominant position by hiking the drug's price by nearly 6,000% over ten years, overcharging the NHS by more than £100 million. The production costs had remained stable, making the price increase unjustifiable and unethical. Relief finally came when new suppliers entered the market. Morningside Healthcare and Teva were granted licenses to produce liothyronine, breaking Concordia's monopoly. With the competition driving prices down, Sarah could once again afford her medication. She felt a renewed sense of hope, not just for herself but for all those affected by hypothyroidism who depended on this vital drug."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
gpt-4o-2024-08-06	"Concordia International, a Canadian pharmaceutical company, has come under scrutiny for allegedly overcharging the UK's National Health Service (NHS) by more than £100 million over the past decade. The Competition and Markets Authority (CMA), Britain's competition watchdog, has provisionally concluded that Concordia exploited its dominant market position to inflate the price of liothyronine, a crucial thyroid medication, by nearly 6,000% from 2007 to 2017. This dramatic price increase has placed a significant financial burden on the NHS, which spent over £34 million on the drug last year alone, compared to just £600,000 in 2006. The cost per pack of the medication skyrocketed from £4.46 in 2007 to £258.19 by July 2017, with the price of a single pill rising from 16p to £9.22, despite stable production costs during this period. Strategy plays a crucial role in Concordia's pricing decisions, as the company was the sole supplier of liothyronine until recently. This lack of competition allowed Concordia to set prices without fear of losing market share, as patients with hypothyroidism, a condition affecting at least two in 100 people, had no alternative treatment options. The drug, a synthetic version of the hormone T3, is essential for patients who do not respond well to the more affordable levothyroxine. The CMA's findings suggest that Concordia's pricing strategy was not only aggressive but also exploitative, taking advantage of the NHS's reliance on the drug to treat patients with an underactive thyroid. The potential consequences for Concordia are significant, as the company could face a fine of up to 10% of its worldwide annual turnover if the CMA's provisional findings are confirmed. This case highlights the broader issue of pharmaceutical companies leveraging their market dominance to impose exorbitant prices on essential medications, raising ethical questions about the balance between profit and patient care. The CMA's investigation serves as a warning to other companies that such practices will not go unchecked and that regulatory bodies are prepared to take action to protect public health interests. In response to the situation, the UK has taken steps to introduce competition into the market for liothyronine. This summer, Morningside Healthcare, a UK-based firm, and Teva, an Israeli pharmaceutical company, were granted licenses to supply the drug. The entry of these new suppliers is expected to drive down prices and provide the NHS with more affordable options for treating hypothyroidism. This development underscores the importance of fostering a competitive market environment to ensure that life-saving medications remain accessible and affordable for all patients."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
DeepSeek-Coder-V2-Lite-Instruct	"Concordia International, a prominent Canadian pharmaceutical company, has been found to have overcharged the National Health Service (NHS) in the UK by more than £100 million over the past decade for a crucial thyroid drug, according to the UK’s competition watchdog. The Competition and Markets Authority (CMA) has provisionally determined that Concordia abused its dominant position in the market to unjustly increase the cost of liothyronine, a medication used to treat patients with an underactive thyroid, by nearly 6,000% between 2007 and 2017. This significant price hike has resulted in the NHS spending more than £34 million on the drug last year, a considerable increase from about £600,000 in 2006. The cost per pack of liothyronine has escalated from £4.46 in 2007 to £258.19 by July 2017, while the price of a single pill has surged from 16p to £9.22. Despite stable production costs during this period, the CMA asserts that Concordia’s pricing strategy has been exploitative. If found guilty, Concordia could face fines up to 10% of its global annual turnover. Liothyronine tablets are essential for treating hypothyroidism, a condition caused by a deficiency of the thyroid hormone, affecting approximately two in every 100 people and potentially leading to symptoms such as depression, tiredness, and weight gain. Until this year, Concordia was the sole supplier of the drug, but this summer, the UK’s Morningside Healthcare and Israel’s Teva were granted licenses to provide the medication as alternatives."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
Meta-Llama-3.1-405B-Instruct-Turbo	"The news of Concordia International's price gouging on the life-changing thyroid drug liothyronine sent shockwaves through the medical community. The Canadian drug company had been accused by Britain's competition watchdog, the Competition and Markets Authority (CMA), of overcharging the NHS by more than £100m in the past decade. Patients who relied on the medication to manage their hypothyroidism were outraged, having seen the price of a single pill skyrocket from 16p to £9.22 over the course of a decade. Strategy was at the heart of Concordia's actions, according to the CMA. By exploiting its dominant position in the market, the company was able to hike the price of liothyronine by nearly 6,000% between 2007 and 2017. The regulator alleged that Concordia had taken advantage of the fact that there was no alternative supplier of the drug, leaving the NHS with no choice but to pay the inflated prices. The CMA's provisional findings suggested that Concordia's actions had cost the NHS dearly, with the health service spending more than £34m on the drug last year alone. For patients like Sarah, who has been taking liothyronine for several years to manage her hypothyroidism, the news was a bitter pill to swallow. She had noticed the price of her medication increasing over the years, but had no idea that Concordia was behind the price hikes. 'I'm appalled by the company's actions,' she said. 'It's not just the NHS that's been affected - it's patients like me who have had to pay the price for Concordia's greed.' The CMA's investigation has brought hope to patients like Sarah, who may finally see some justice. The consequences for Concordia could be severe, with the company facing a potential fine of up to 10% of its worldwide annual turnover. The CMA's findings have also led to increased competition in the market, with two new suppliers - Morningside Healthcare and Teva - being granted licences to supply the drug. For patients who rely on liothyronine, the news is a welcome development, and a sign that the tide may finally be turning in their favour."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
Meta-Llama-3.1-70B-Instruct-Turbo	"The Canadian drug company Concordia International has been accused of overcharging the NHS by more than £100m in the past decade for a life-changing thyroid drug. The company's pricing tactics have been deemed an abuse of its dominant position in the market by Britain's competition watchdog, the Competition and Markets Authority (CMA). The CMA's provisional findings suggest that Concordia hiked the price of liothyronine, a drug used to treat patients with an underactive thyroid, by nearly 6,000% between 2007 and 2017. Strategy was clearly at play when Concordia decided to increase the price of liothyronine, as the company knew it had a captive market. The NHS had no choice but to pay the inflated prices, as Concordia was the only supplier of the drug until this year. The regulator's investigation found that the NHS spent more than £34m on the drug last year, up from about £600,000 in 2006. The amount it paid per pack rose from £4.46 in 2007 to £258.19 by July 2017. The price hike was not justified by any increase in production costs, which remained broadly stable during the period. In fact, the price of a single pill went up from 16p to £9.22, a staggering increase that has left many patients and healthcare professionals outraged. Liothyronine tablets are used to treat hypothyroidism, a condition that affects at least two in 100 people and can lead to depression, tiredness, and weight gain. For many patients, there is no alternative to this drug, making Concordia's pricing tactics all the more egregious. Concordia could face severe penalties for its actions, including a fine of up to 10% of its worldwide annual turnover. The company's dominance in the market has been broken, however, with the UK firm Morningside Healthcare and Israel's Teva being granted licences to supply the drug this summer. The introduction of new suppliers is expected to increase competition and drive down prices, bringing much-needed relief to patients and the NHS."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
Qwen2-72B-Instruct	"Concordia International, a Canadian pharmaceutical company, is facing severe allegations from Britain's Competition and Markets Authority (CMA) for overcharging the National Health Service (NHS) by more than £100 million over the past decade. The CMA has provisionally found that Concordia abused its dominant market position to inflate the price of liothyronine, a critical drug for treating hypothyroidism, by nearly 6,000% between 2007 and 2017. This price hike has resulted in the NHS spending over £34 million on the drug in 2017 alone, a stark contrast to the £600,000 it spent in 2006." "Strategy to address the issue, the CMA is considering imposing a fine on Concordia that could amount to up to 10% of its worldwide annual turnover. The authority's investigation revealed that the price per pack of liothyronine soared from £4.46 in 2007 to £258.19 by July 2017, while the cost of a single pill escalated from 16p to £9.22. These price increases occurred despite stable production costs, according to the CMA. The drug, which is a synthetic version of the hormone T3, is crucial for patients who do not respond well to the more affordable alternative, levothyroxine." "Concordia's actions have had a significant impact on patients suffering from hypothyroidism, a condition that affects at least two in 100 people and can lead to symptoms such as depression, tiredness, and weight gain. For many of these patients, liothyronine is the only effective treatment, and until recently, Concordia was the sole supplier. This monopoly allowed the company to drastically increase prices without fear of losing customers to competitors." "However, the landscape has changed this summer with the UK firm Morningside Healthcare and Israel’s Teva being granted licenses to supply liothyronine. This development is expected to increase competition and potentially lead to more affordable pricing for the NHS and patients. The CMA's investigation and potential fines serve as a warning to pharmaceutical companies about the consequences of exploiting their market dominance to the detriment of public health services and patients."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
baichuan4	"Concordia International, a Canadian drug company, has been accused of overcharging the National Health Service (NHS) by more than £100 million in the past decade for a crucial thyroid medication. According to Britain's competition watchdog, the Competition and Markets Authority (CMA), Concordia is suspected of abusing its dominant market position to dramatically increase the price of liothyronine, a drug used to treat patients with an underactive thyroid. Between 2007 and 2017, the price of this life-changing medication soared by nearly 6,000%. The financial burden on the NHS has been immense, with expenditures on the drug rising from approximately £600,000 in 2006 to over £34 million in the last year alone. The cost per pack skyrocketed from £4.46 in 2007 to £258.19 by July 2017, while the price of a single pill escalated from 16p to £9.22. Despite these staggering price hikes, the CMA noted that production costs for the drug remained relatively stable throughout the period in question. Strategy employed by Concordia to maintain its monopoly on the supply of liothyronine involved leveraging its exclusive position in the market to enforce these exorbitant price increases. Until recently, Concordia was the sole supplier of this essential medication, leaving the NHS with no alternative but to pay the inflated prices. The drug is critical for patients suffering from hypothyroidism, a condition resulting from a deficiency of thyroid hormones, which affects at least two in every hundred people. Symptoms of hypothyroidism include depression, fatigue, and weight gain, making the availability of effective treatment paramount. Liothyronine tablets, a synthetic version of the hormone T3, are particularly important for those patients who do not respond adequately to the cheaper alternative, levothyroxine. The situation began to change this year when the UK firm Morningside Healthcare and Israel's Teva were granted licenses to supply liothyronine, breaking Concordia's monopoly. This development is expected to introduce much-needed competition into the market, potentially leading to more reasonable pricing for the NHS and better accessibility for patients. However, the legacy of Concordia's pricing strategy remains a significant concern, with the CMA considering imposing a fine of up to 10% of Concordia's worldwide annual turnover as a penalty for the alleged abuse of its dominant market position. As the investigation by the CMA progresses, the healthcare community and patients alike watch with anticipation to see how this case will unfold. The outcome could have far-reaching implications for the pharmaceutical industry, setting a precedent for how companies are allowed to price their medications, especially when they hold a dominant position in the market. For the NHS, the resolution of this case could mean significant savings and a reprieve from the financial strain imposed by Concordia's pricing practices. Most importantly, it could ensure that patients in need of life-changing medications like liothyronine have access to them at a fair and reasonable cost."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
doubao	"Concordia International, a Canadian drug company, has been accused by Britain's competition watchdog of overcharging the NHS by more than £100m in the past decade for a thyroid drug. The Competition and Markets Authority (CMA) found that Concordia had abused its dominant position by hiking the price of liothyronine by nearly 6,000% between 2007 and 2017. The regulator stated that the NHS spent over £34m on the drug last year, compared to about £600,000 in 2006. The price per pack rose significantly, and the price of a single pill also increased drastically, even though production costs remained stable. Strategy Concordia could face a fine of up to 10% of its worldwide annual turnover. Liothyronine tablets are crucial for treating hypothyroidism, a condition that affects many people and can lead to various issues. For a long time, Concordia was the sole supplier, but this summer, other firms were granted licences. The medicine, a synthetic version of the hormone T3, is used by patients who don't respond well to the cheaper alternative, levothyroxine. This situation highlights the importance of regulatory oversight to ensure fair pricing and access to essential medications. The case against Concordia serves as a reminder of the need for stronger measures to protect the healthcare system and patients from excessive pricing by dominant companies."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
gpto1	"Sarah had been battling hypothyroidism for years, a condition that left her feeling constantly tired, depressed, and struggling with weight gain. The only medication that managed her symptoms effectively was liothyronine, a life-changing thyroid drug she relied on daily. But over the past decade, she watched in dismay as the price of her essential medication skyrocketed. What once cost her just £4.46 per pack in 2007 had surged to an astounding £258.19 by 2017. Strategy became Sarah's lifeline as she navigated the increasingly unaffordable costs of her medication. She tried everything—from cutting down on other expenses to seeking financial assistance—but nothing seemed to ease the burden. Switching to the cheaper alternative, levothyroxine, wasn't an option; it didn't alleviate her symptoms. With no other suppliers in the market, she felt trapped and helpless. Unbeknownst to Sarah, the Competition and Markets Authority had launched an investigation into Concordia International, the sole supplier of liothyronine. They discovered that the company had abused its dominant position by hiking the drug's price by nearly 6,000% over ten years, overcharging the NHS by more than £100 million. The production costs had remained stable, making the price increase unjustifiable and unethical. Relief finally came when new suppliers entered the market. Morningside Healthcare and Teva were granted licenses to produce liothyronine, breaking Concordia's monopoly. With the competition driving prices down, Sarah could once again afford her medication. She felt a renewed sense of hope, not just for herself but for all those affected by hypothyroidism who depended on this vital drug."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
kimi	"Concordia International, a Canadian pharmaceutical company, has been accused by the UK's Competition and Markets Authority (CMA) of overcharging the National Health Service (NHS) by more than £100 million for a thyroid drug over the past decade. The CMA has provisionally determined that Concordia exploited its dominant position in the market to significantly increase the price of liothyronine, a medication used to treat patients with hypothyroidism, by nearly 6,000% between 2007 and 2017. This aggressive pricing strategy has led to a substantial financial burden on the NHS, with the annual expenditure on the drug skyrocketing from approximately £600,000 in 2006 to over £34 million in the last year alone. The cost per pack of the drug rose from £4.46 in 2007 to £258.19 by July 2017, and the price of a single pill increased from 16p to £9.22, despite stable production costs." "Strategy played a significant role in Concordia's approach to pricing liothyronine. By maintaining a monopoly on the drug's supply until this year, the company was able to implement a strategy of exponential price increases without facing competition. This strategy took advantage of the NHS's reliance on the drug for treating a condition that affects at least two in 100 people, causing symptoms such as depression, tiredness, and weight gain. The lack of alternatives for many patients and the company's sole supplier status allowed Concordia to implement this pricing strategy without immediate repercussions." "The situation has begun to change this summer with the granting of licences to UK firm Morningside Healthcare and Israel’s Teva to supply the drug. This development breaks Concordia's monopoly and introduces competition into the market, which is expected to exert downward pressure on the drug's price. The entry of these new suppliers is a significant step towards alleviating the financial strain on the NHS and ensuring that patients continue to have access to this essential medication." "As a result of the CMA's findings, Concordia could face a substantial financial penalty, with the potential for a fine up to 10% of its worldwide annual turnover. This penalty would serve as a deterrent for similar practices in the future and underscore the importance of fair pricing in the pharmaceutical industry. The CMA's actions highlight the need for ongoing vigilance and regulation to protect public health systems and patients from excessive costs associated with life-saving medications."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
minimax	"Concordia International, the Canadian drug company, has been accused of overcharging the National Health Service (NHS) by more than £100 million over the past decade for a crucial thyroid medication. The Competition and Markets Authority (CMA) has provisionally concluded that Concordia exploited its dominant position to impose exorbitant prices on liothyronine, a drug used to treat patients with an underactive thyroid. The regulator noted that the NHS spent over £34 million on the drug in the last year, a significant increase from the £600,000 spent in 2006. The cost per pack skyrocketed from £4.46 in 2007 to £258.19 by July 2017, while the price per pill surged from 16p to £9.22. Despite this, production costs remained relatively stable, indicating that Concordia's price hikes were not due to increased manufacturing expenses. The strategy employed by Concordia to inflate the prices of liothyronine has drawn severe criticism from the CMA, which has the power to impose fines amounting to 10% of the company's worldwide annual turnover. Liothyron	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
wenxinyiyan	"Concordia International, a Canadian drug company, has been accused by Britain’s competition watchdog of overcharging the National Health Service (NHS) by more than £100 million in the past decade for a thyroid drug. The Competition and Markets Authority (CMA) provisionally found that Concordia abused its dominant market position to hike the price of liothyronine, a drug used to treat hypothyroidism, by nearly 6,000% between 2007 and 2017. \n\nStrategy wise, Concordia seemed to have capitalized on its position as the sole supplier of the drug in the UK market, raising prices exorbitantly. The NHS expenditure on the drug skyrocketed from about £600,000 in 2006 to over £34 million last year. The cost per pack increased from £4.46 in 2007 to a staggering £258.19 by July 2017, even though production costs had remained stable. \n\nLiothyronine is a crucial medication for patients with hypothyroidism, a condition that affects at least two in 100 people and can cause depression, fatigue, and weight gain. Many patients have no alternative treatment, and until recently, Concordia was the only supplier. However, this summer, two new companies, Morningside Healthcare from the UK and Teva from Israel, were granted licences to supply the drug, potentially breaking Concordia’s monopoly. \n\nConcordia now faces a possible fine of up to 10% of its annual global turnover for its apparent price-gouging practices. The CMA’s investigation and subsequent ruling serve as a reminder to pharmaceutical companies that exploiting their market position for excessive profits will not be tolerated. Meanwhile, patients and healthcare providers alike await the final outcome of this case, which could have significant implications for the future of drug pricing and supply in the UK."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
zhipu	"Concordia International, a prominent Canadian pharmaceutical company, has come under fire for allegedly overcharging the UK's National Health Service (NHS) by over £100 million over the past decade. The Competition and Markets Authority (CMA) revealed its preliminary findings, accusing Concordia of exploiting its dominant market position to inflate the price of liothyronine, a critical drug for treating underactive thyroid conditions. The price surge was astronomical, with the cost of liothyronine skyrocketing by nearly 6,000% between 2007 and 2017. This drastic increase saw the NHS's expenditure on the drug balloon from approximately £600,000 in 2006 to a staggering £34 million in the past year alone. Strategy seemed to be at the heart of Concordia's actions, as the company systematically raised the price per pack from £4.46 in 2007 to an eye-watering £258.19 by July 2017. The cost of a single pill jumped from 16p to £9.22, despite production costs remaining relatively stable over the same period. The CMA's investigation highlighted the stark disparity between the soaring prices and the unchanged manufacturing expenses, suggesting a deliberate move to maximize profits at the expense of public health funding. If found guilty, Concordia could face a hefty fine of up to 10% of its global annual turnover, underscoring the severity of the allegations. Liothyronine tablets are essential for treating hypothyroidism, a condition affecting at least two in every 100 people and characterized by symptoms like depression, fatigue, and weight gain. For many patients, there are no viable alternatives to this medication, making Concordia's monopoly particularly troubling. Until recently, Concordia was the sole supplier of liothyronine in the UK, giving it unprecedented control over the market and pricing. This situation left the NHS and patients vulnerable to the company's pricing strategies, with no other options to turn to for this life-changing treatment. However, a glimmer of hope emerged this summer when the UK firm Morningside Healthcare and Israel’s Teva were granted licences to supply liothyronine. This development introduced much-needed competition into the market, potentially easing the financial burden on the NHS and ensuring more affordable access to the drug for patients. The synthetic hormone T3, which liothyronine replicates, remains crucial for those who do not respond well to the cheaper alternative, levothyroxine. As the investigation continues, the healthcare community and patients alike await the outcome, hoping for justice and a resolution that prioritizes public health over profit margins."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']
deepseek-v3	"Concordia International, a Canadian pharmaceutical company, has been accused of overcharging the NHS by more than £100 million over the past decade for a critical thyroid medication, liothyronine. According to Britain’s Competition and Markets Authority (CMA), Concordia exploited its dominant market position to inflate the drug’s price by nearly 6,000% between 2007 and 2017. During this period, the NHS’s expenditure on liothyronine skyrocketed from approximately £600,000 in 2006 to over £34 million in 2022. The cost per pack surged from £4.46 in 2007 to £258.19 by July 2017, with the price of a single pill jumping from 16p to £9.22, despite production costs remaining stable. The CMA has warned that Concordia could face fines of up to 10% of its global annual turnover for this alleged abuse. Strategy played a central role in Concordia’s actions, as the company leveraged its monopoly on liothyronine to impose exorbitant price hikes. Liothyronine, a synthetic version of the thyroid hormone T3, is a lifeline for patients with hypothyroidism who do not respond to the cheaper alternative, levothyroxine. With no other suppliers in the market until recently, Concordia held a near-exclusive grip on the drug, leaving the NHS with little choice but to pay the inflated prices. This exploitation of a vulnerable patient population has drawn widespread criticism, particularly as hypothyroidism affects at least two in 100 people and can lead to severe symptoms like depression, fatigue, and weight gain. The situation began to shift earlier this year when the UK’s Morningside Healthcare and Israel’s Teva were granted licenses to supply liothyronine, breaking Concordia’s monopoly. This development has been hailed as a significant step toward reducing the financial burden on the NHS and ensuring patients have access to affordable treatment. However, the damage done over the past decade underscores the need for stricter oversight of pharmaceutical pricing practices. The CMA’s investigation highlights the critical importance of preventing companies from exploiting their market dominance at the expense of public health systems and patients. Concordia’s case is a stark reminder of the ethical responsibilities pharmaceutical companies bear in delivering life-saving medications. While the company has yet to respond publicly to the CMA’s findings, the potential fines and reputational damage could have far-reaching consequences. For the NHS and patients, the entry of new suppliers offers hope for a more equitable and sustainable future. As the healthcare system continues to grapple with the financial pressures of rising drug costs, this case serves as a call to action for greater transparency and accountability in the pharmaceutical industry."	['startend:quotation' 'length_constraints:nth_paragraph_first_word']

模型

模型答案

正确答案

金声玉亮2.0

"Concordia International, a Canadian pharmaceutical company, has been accused by Britain's Competition and Markets Authority (CMA) of exploiting its dominant market position to overcharge the National Health Service (NHS) by more than £100 million over the past decade for a critical thyroid medication. The CMA's investigation revealed that Concordia dramatically increased the price of liothyronine, a drug used to treat hypothyroidism, by nearly 6,000% between 2007 and 2017, leaving the NHS to bear the brunt of these exorbitant costs. The regulator's findings highlight a stark example of how pharmaceutical companies can wield their market power to the detriment of public health systems and patients alike.

Strategy employed by Concordia involved capitalizing on the drug's essential nature and lack of alternatives, as liothyronine is crucial for patients who do not respond well to cheaper alternatives like levothyroxine. The company's pricing strategy saw the cost of a single pill skyrocket from 16p to £9.22, despite stable production costs, demonstrating a clear abuse of its dominant position in the market. This aggressive pricing tactic not only inflated Concordia's profits but also placed a significant financial burden on the NHS, which spent over £34 million on the drug in a single year, a drastic increase from the £600,000 spent in 2006.

The CMA's provisional findings have significant implications for Concordia, as the company could face fines of up to 10% of its worldwide annual turnover. This penalty, if enforced, would serve as a deterrent to other pharmaceutical companies considering similar pricing strategies. Moreover, the case highlights the urgent need for regulatory oversight in the pharmaceutical industry to prevent such practices from harming patients and overburdening healthcare systems.

In response to the CMA's investigation, Concordia has come under scrutiny, prompting a shift in the market dynamics. This summer, UK-based Morningside Healthcare and Israeli pharmaceutical company Teva were granted licenses to supply liothyronine, introducing much-needed competition into the market. This development offers hope for a more balanced and fairer approach to drug pricing, potentially benefiting the NHS and patients by reducing costs and increasing access to this life-changing medication."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

deepseek-r1

"In a stark revelation that has sent shockwaves through the UK healthcare system, the Competition and Markets Authority (CMA) has accused Concordia International, a Canadian pharmaceutical giant, of exploiting its monopoly to overcharge the NHS by over £100 million for a critical thyroid medication. The drug, liothyronine, used by patients with hypothyroidism to regulate hormone levels, saw its price surge by an astonishing 6,000% between 2007 and 2017. During this period, the NHS’s annual spending on the medication ballooned from £600,000 to £34 million, with the cost per pack escalating from £4.46 to £258.19. The CMA emphasized that production costs remained stable, accusing Concordia of 'abusing its dominant position' to impose unjustifiable price hikes on a drug vital for patients who cannot tolerate cheaper alternatives like levothyroxine.

\n\nStrategy lay at the heart of Concordia’s alleged exploitation. By maintaining a near-total monopoly on liothyronine—a synthetic thyroid hormone known as T3—the company faced no competitive pressure to keep prices in check. This allowed it to steadily inflate costs, capitalizing on the fact that, until 2023, no other suppliers were licensed to offer the drug in the UK. Patients reliant on liothyronine, often those with severe symptoms like chronic fatigue and mental health struggles, had no choice but to pay the soaring prices or risk deteriorating health. The CMA’s provisional findings suggest Concordia’s pricing strategy was not merely aggressive but predatory, leveraging the desperation of vulnerable individuals and the NHS’s obligation to provide life-saving treatments.

\n\nThe human toll of Concordia’s actions has been profound. Hypothyroidism affects approximately 2% of the UK population, and for many, liothyronine is the only effective treatment. Stories have emerged of patients rationing pills or skipping doses due to the drug’s exorbitant cost, even as the NHS absorbed the financial blow. One patient, speaking anonymously, described the price hikes as 'a tax on staying functional,' highlighting the anxiety of depending on a medication whose cost seemed to defy reason. Meanwhile, the NHS, already stretched thin, diverted millions from other critical services to cover the spiraling expense—a burden that critics argue compromised care for countless others.

\n\nRecent developments may signal a turning point. This summer, the UK’s Morningside Healthcare and Israel’s Teva Pharmaceuticals secured licenses to supply liothyronine, breaking Concordia’s monopoly. The CMA’s ongoing investigation could also lead to fines exceeding 10% of Concordia’s global revenue—a penalty that would set a precedent in curbing pharmaceutical profiteering. While the company denies wrongdoing, calling the allegations 'misplaced,' the case has ignited calls for stricter oversight of drug pricing. For patients and the NHS alike, the hope is that competition will restore fairness to a market where lives, not profits, should come first."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

gpto1

"Sarah had been battling hypothyroidism for years, a condition that left her feeling constantly tired, depressed, and struggling with weight gain. The only medication that managed her symptoms effectively was liothyronine, a life-changing thyroid drug she relied on daily. But over the past decade, she watched in dismay as the price of her essential medication skyrocketed. What once cost her just £4.46 per pack in 2007 had surged to an astounding £258.19 by 2017.

Strategy became Sarah's lifeline as she navigated the increasingly unaffordable costs of her medication. She tried everything—from cutting down on other expenses to seeking financial assistance—but nothing seemed to ease the burden. Switching to the cheaper alternative, levothyroxine, wasn't an option; it didn't alleviate her symptoms. With no other suppliers in the market, she felt trapped and helpless.

Unbeknownst to Sarah, the Competition and Markets Authority had launched an investigation into Concordia International, the sole supplier of liothyronine. They discovered that the company had abused its dominant position by hiking the drug's price by nearly 6,000% over ten years, overcharging the NHS by more than £100 million. The production costs had remained stable, making the price increase unjustifiable and unethical.

Relief finally came when new suppliers entered the market. Morningside Healthcare and Teva were granted licenses to produce liothyronine, breaking Concordia's monopoly. With the competition driving prices down, Sarah could once again afford her medication. She felt a renewed sense of hope, not just for herself but for all those affected by hypothyroidism who depended on this vital drug."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

gpt-4o-2024-08-06

"Concordia International, a Canadian pharmaceutical company, has come under scrutiny for allegedly overcharging the UK's National Health Service (NHS) by more than £100 million over the past decade. The Competition and Markets Authority (CMA), Britain's competition watchdog, has provisionally concluded that Concordia exploited its dominant market position to inflate the price of liothyronine, a crucial thyroid medication, by nearly 6,000% from 2007 to 2017. This dramatic price increase has placed a significant financial burden on the NHS, which spent over £34 million on the drug last year alone, compared to just £600,000 in 2006. The cost per pack of the medication skyrocketed from £4.46 in 2007 to £258.19 by July 2017, with the price of a single pill rising from 16p to £9.22, despite stable production costs during this period.

Strategy plays a crucial role in Concordia's pricing decisions, as the company was the sole supplier of liothyronine until recently. This lack of competition allowed Concordia to set prices without fear of losing market share, as patients with hypothyroidism, a condition affecting at least two in 100 people, had no alternative treatment options. The drug, a synthetic version of the hormone T3, is essential for patients who do not respond well to the more affordable levothyroxine. The CMA's findings suggest that Concordia's pricing strategy was not only aggressive but also exploitative, taking advantage of the NHS's reliance on the drug to treat patients with an underactive thyroid.

The potential consequences for Concordia are significant, as the company could face a fine of up to 10% of its worldwide annual turnover if the CMA's provisional findings are confirmed. This case highlights the broader issue of pharmaceutical companies leveraging their market dominance to impose exorbitant prices on essential medications, raising ethical questions about the balance between profit and patient care. The CMA's investigation serves as a warning to other companies that such practices will not go unchecked and that regulatory bodies are prepared to take action to protect public health interests.

In response to the situation, the UK has taken steps to introduce competition into the market for liothyronine. This summer, Morningside Healthcare, a UK-based firm, and Teva, an Israeli pharmaceutical company, were granted licenses to supply the drug. The entry of these new suppliers is expected to drive down prices and provide the NHS with more affordable options for treating hypothyroidism. This development underscores the importance of fostering a competitive market environment to ensure that life-saving medications remain accessible and affordable for all patients."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

DeepSeek-Coder-V2-Lite-Instruct

"Concordia International, a prominent Canadian pharmaceutical company, has been found to have overcharged the National Health Service (NHS) in the UK by more than £100 million over the past decade for a crucial thyroid drug, according to the UK’s competition watchdog. The Competition and Markets Authority (CMA) has provisionally determined that Concordia abused its dominant position in the market to unjustly increase the cost of liothyronine, a medication used to treat patients with an underactive thyroid, by nearly 6,000% between 2007 and 2017. This significant price hike has resulted in the NHS spending more than £34 million on the drug last year, a considerable increase from about £600,000 in 2006. The cost per pack of liothyronine has escalated from £4.46 in 2007 to £258.19 by July 2017, while the price of a single pill has surged from 16p to £9.22. Despite stable production costs during this period, the CMA asserts that Concordia’s pricing strategy has been exploitative. If found guilty, Concordia could face fines up to 10% of its global annual turnover. Liothyronine tablets are essential for treating hypothyroidism, a condition caused by a deficiency of the thyroid hormone, affecting approximately two in every 100 people and potentially leading to symptoms such as depression, tiredness, and weight gain. Until this year, Concordia was the sole supplier of the drug, but this summer, the UK’s Morningside Healthcare and Israel’s Teva were granted licenses to provide the medication as alternatives."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

Meta-Llama-3.1-405B-Instruct-Turbo

"The news of Concordia International's price gouging on the life-changing thyroid drug liothyronine sent shockwaves through the medical community. The Canadian drug company had been accused by Britain's competition watchdog, the Competition and Markets Authority (CMA), of overcharging the NHS by more than £100m in the past decade. Patients who relied on the medication to manage their hypothyroidism were outraged, having seen the price of a single pill skyrocket from 16p to £9.22 over the course of a decade.

Strategy was at the heart of Concordia's actions, according to the CMA. By exploiting its dominant position in the market, the company was able to hike the price of liothyronine by nearly 6,000% between 2007 and 2017. The regulator alleged that Concordia had taken advantage of the fact that there was no alternative supplier of the drug, leaving the NHS with no choice but to pay the inflated prices. The CMA's provisional findings suggested that Concordia's actions had cost the NHS dearly, with the health service spending more than £34m on the drug last year alone.

For patients like Sarah, who has been taking liothyronine for several years to manage her hypothyroidism, the news was a bitter pill to swallow. She had noticed the price of her medication increasing over the years, but had no idea that Concordia was behind the price hikes. 'I'm appalled by the company's actions,' she said. 'It's not just the NHS that's been affected - it's patients like me who have had to pay the price for Concordia's greed.' The CMA's investigation has brought hope to patients like Sarah, who may finally see some justice.

The consequences for Concordia could be severe, with the company facing a potential fine of up to 10% of its worldwide annual turnover. The CMA's findings have also led to increased competition in the market, with two new suppliers - Morningside Healthcare and Teva - being granted licences to supply the drug. For patients who rely on liothyronine, the news is a welcome development, and a sign that the tide may finally be turning in their favour."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

Meta-Llama-3.1-70B-Instruct-Turbo

"The Canadian drug company Concordia International has been accused of overcharging the NHS by more than £100m in the past decade for a life-changing thyroid drug. The company's pricing tactics have been deemed an abuse of its dominant position in the market by Britain's competition watchdog, the Competition and Markets Authority (CMA). The CMA's provisional findings suggest that Concordia hiked the price of liothyronine, a drug used to treat patients with an underactive thyroid, by nearly 6,000% between 2007 and 2017.

Strategy was clearly at play when Concordia decided to increase the price of liothyronine, as the company knew it had a captive market. The NHS had no choice but to pay the inflated prices, as Concordia was the only supplier of the drug until this year. The regulator's investigation found that the NHS spent more than £34m on the drug last year, up from about £600,000 in 2006. The amount it paid per pack rose from £4.46 in 2007 to £258.19 by July 2017.

The price hike was not justified by any increase in production costs, which remained broadly stable during the period. In fact, the price of a single pill went up from 16p to £9.22, a staggering increase that has left many patients and healthcare professionals outraged. Liothyronine tablets are used to treat hypothyroidism, a condition that affects at least two in 100 people and can lead to depression, tiredness, and weight gain. For many patients, there is no alternative to this drug, making Concordia's pricing tactics all the more egregious.

Concordia could face severe penalties for its actions, including a fine of up to 10% of its worldwide annual turnover. The company's dominance in the market has been broken, however, with the UK firm Morningside Healthcare and Israel's Teva being granted licences to supply the drug this summer. The introduction of new suppliers is expected to increase competition and drive down prices, bringing much-needed relief to patients and the NHS."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

Qwen2-72B-Instruct

"Concordia International, a Canadian pharmaceutical company, is facing severe allegations from Britain's Competition and Markets Authority (CMA) for overcharging the National Health Service (NHS) by more than £100 million over the past decade. The CMA has provisionally found that Concordia abused its dominant market position to inflate the price of liothyronine, a critical drug for treating hypothyroidism, by nearly 6,000% between 2007 and 2017. This price hike has resulted in the NHS spending over £34 million on the drug in 2017 alone, a stark contrast to the £600,000 it spent in 2006."

"Strategy to address the issue, the CMA is considering imposing a fine on Concordia that could amount to up to 10% of its worldwide annual turnover. The authority's investigation revealed that the price per pack of liothyronine soared from £4.46 in 2007 to £258.19 by July 2017, while the cost of a single pill escalated from 16p to £9.22. These price increases occurred despite stable production costs, according to the CMA. The drug, which is a synthetic version of the hormone T3, is crucial for patients who do not respond well to the more affordable alternative, levothyroxine."

"Concordia's actions have had a significant impact on patients suffering from hypothyroidism, a condition that affects at least two in 100 people and can lead to symptoms such as depression, tiredness, and weight gain. For many of these patients, liothyronine is the only effective treatment, and until recently, Concordia was the sole supplier. This monopoly allowed the company to drastically increase prices without fear of losing customers to competitors."

"However, the landscape has changed this summer with the UK firm Morningside Healthcare and Israel’s Teva being granted licenses to supply liothyronine. This development is expected to increase competition and potentially lead to more affordable pricing for the NHS and patients. The CMA's investigation and potential fines serve as a warning to pharmaceutical companies about the consequences of exploiting their market dominance to the detriment of public health services and patients."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

baichuan4

"Concordia International, a Canadian drug company, has been accused of overcharging the National Health Service (NHS) by more than £100 million in the past decade for a crucial thyroid medication. According to Britain's competition watchdog, the Competition and Markets Authority (CMA), Concordia is suspected of abusing its dominant market position to dramatically increase the price of liothyronine, a drug used to treat patients with an underactive thyroid. Between 2007 and 2017, the price of this life-changing medication soared by nearly 6,000%. The financial burden on the NHS has been immense, with expenditures on the drug rising from approximately £600,000 in 2006 to over £34 million in the last year alone. The cost per pack skyrocketed from £4.46 in 2007 to £258.19 by July 2017, while the price of a single pill escalated from 16p to £9.22. Despite these staggering price hikes, the CMA noted that production costs for the drug remained relatively stable throughout the period in question.

Strategy employed by Concordia to maintain its monopoly on the supply of liothyronine involved leveraging its exclusive position in the market to enforce these exorbitant price increases. Until recently, Concordia was the sole supplier of this essential medication, leaving the NHS with no alternative but to pay the inflated prices. The drug is critical for patients suffering from hypothyroidism, a condition resulting from a deficiency of thyroid hormones, which affects at least two in every hundred people. Symptoms of hypothyroidism include depression, fatigue, and weight gain, making the availability of effective treatment paramount. Liothyronine tablets, a synthetic version of the hormone T3, are particularly important for those patients who do not respond adequately to the cheaper alternative, levothyroxine.

The situation began to change this year when the UK firm Morningside Healthcare and Israel's Teva were granted licenses to supply liothyronine, breaking Concordia's monopoly. This development is expected to introduce much-needed competition into the market, potentially leading to more reasonable pricing for the NHS and better accessibility for patients. However, the legacy of Concordia's pricing strategy remains a significant concern, with the CMA considering imposing a fine of up to 10% of Concordia's worldwide annual turnover as a penalty for the alleged abuse of its dominant market position.

As the investigation by the CMA progresses, the healthcare community and patients alike watch with anticipation to see how this case will unfold. The outcome could have far-reaching implications for the pharmaceutical industry, setting a precedent for how companies are allowed to price their medications, especially when they hold a dominant position in the market. For the NHS, the resolution of this case could mean significant savings and a reprieve from the financial strain imposed by Concordia's pricing practices. Most importantly, it could ensure that patients in need of life-changing medications like liothyronine have access to them at a fair and reasonable cost."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

doubao

"Concordia International, a Canadian drug company, has been accused by Britain's competition watchdog of overcharging the NHS by more than £100m in the past decade for a thyroid drug. The Competition and Markets Authority (CMA) found that Concordia had abused its dominant position by hiking the price of liothyronine by nearly 6,000% between 2007 and 2017. The regulator stated that the NHS spent over £34m on the drug last year, compared to about £600,000 in 2006. The price per pack rose significantly, and the price of a single pill also increased drastically, even though production costs remained stable.

Strategy Concordia could face a fine of up to 10% of its worldwide annual turnover. Liothyronine tablets are crucial for treating hypothyroidism, a condition that affects many people and can lead to various issues. For a long time, Concordia was the sole supplier, but this summer, other firms were granted licences.

The medicine, a synthetic version of the hormone T3, is used by patients who don't respond well to the cheaper alternative, levothyroxine. This situation highlights the importance of regulatory oversight to ensure fair pricing and access to essential medications.

The case against Concordia serves as a reminder of the need for stronger measures to protect the healthcare system and patients from excessive pricing by dominant companies."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

gpto1

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

kimi

"Concordia International, a Canadian pharmaceutical company, has been accused by the UK's Competition and Markets Authority (CMA) of overcharging the National Health Service (NHS) by more than £100 million for a thyroid drug over the past decade. The CMA has provisionally determined that Concordia exploited its dominant position in the market to significantly increase the price of liothyronine, a medication used to treat patients with hypothyroidism, by nearly 6,000% between 2007 and 2017. This aggressive pricing strategy has led to a substantial financial burden on the NHS, with the annual expenditure on the drug skyrocketing from approximately £600,000 in 2006 to over £34 million in the last year alone. The cost per pack of the drug rose from £4.46 in 2007 to £258.19 by July 2017, and the price of a single pill increased from 16p to £9.22, despite stable production costs."

"Strategy played a significant role in Concordia's approach to pricing liothyronine. By maintaining a monopoly on the drug's supply until this year, the company was able to implement a strategy of exponential price increases without facing competition. This strategy took advantage of the NHS's reliance on the drug for treating a condition that affects at least two in 100 people, causing symptoms such as depression, tiredness, and weight gain. The lack of alternatives for many patients and the company's sole supplier status allowed Concordia to implement this pricing strategy without immediate repercussions."

"The situation has begun to change this summer with the granting of licences to UK firm Morningside Healthcare and Israel’s Teva to supply the drug. This development breaks Concordia's monopoly and introduces competition into the market, which is expected to exert downward pressure on the drug's price. The entry of these new suppliers is a significant step towards alleviating the financial strain on the NHS and ensuring that patients continue to have access to this essential medication."

"As a result of the CMA's findings, Concordia could face a substantial financial penalty, with the potential for a fine up to 10% of its worldwide annual turnover. This penalty would serve as a deterrent for similar practices in the future and underscore the importance of fair pricing in the pharmaceutical industry. The CMA's actions highlight the need for ongoing vigilance and regulation to protect public health systems and patients from excessive costs associated with life-saving medications."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

minimax

"Concordia International, the Canadian drug company, has been accused of overcharging the National Health Service (NHS) by more than £100 million over the past decade for a crucial thyroid medication. The Competition and Markets Authority (CMA) has provisionally concluded that Concordia exploited its dominant position to impose exorbitant prices on liothyronine, a drug used to treat patients with an underactive thyroid. The regulator noted that the NHS spent over £34 million on the drug in the last year, a significant increase from the £600,000 spent in 2006. The cost per pack skyrocketed from £4.46 in 2007 to £258.19 by July 2017, while the price per pill surged from 16p to £9.22. Despite this, production costs remained relatively stable, indicating that Concordia's price hikes were not due to increased manufacturing expenses.

The strategy employed by Concordia to inflate the prices of liothyronine has drawn severe criticism from the CMA, which has the power to impose fines amounting to 10% of the company's worldwide annual turnover. Liothyron

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

wenxinyiyan

"Concordia International, a Canadian drug company, has been accused by Britain’s competition watchdog of overcharging the National Health Service (NHS) by more than £100 million in the past decade for a thyroid drug. The Competition and Markets Authority (CMA) provisionally found that Concordia abused its dominant market position to hike the price of liothyronine, a drug used to treat hypothyroidism, by nearly 6,000% between 2007 and 2017.

\n\nStrategy wise, Concordia seemed to have capitalized on its position as the sole supplier of the drug in the UK market, raising prices exorbitantly. The NHS expenditure on the drug skyrocketed from about £600,000 in 2006 to over £34 million last year. The cost per pack increased from £4.46 in 2007 to a staggering £258.19 by July 2017, even though production costs had remained stable.

\n\nLiothyronine is a crucial medication for patients with hypothyroidism, a condition that affects at least two in 100 people and can cause depression, fatigue, and weight gain. Many patients have no alternative treatment, and until recently, Concordia was the only supplier. However, this summer, two new companies, Morningside Healthcare from the UK and Teva from Israel, were granted licences to supply the drug, potentially breaking Concordia’s monopoly.

\n\nConcordia now faces a possible fine of up to 10% of its annual global turnover for its apparent price-gouging practices. The CMA’s investigation and subsequent ruling serve as a reminder to pharmaceutical companies that exploiting their market position for excessive profits will not be tolerated. Meanwhile, patients and healthcare providers alike await the final outcome of this case, which could have significant implications for the future of drug pricing and supply in the UK."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

zhipu

"Concordia International, a prominent Canadian pharmaceutical company, has come under fire for allegedly overcharging the UK's National Health Service (NHS) by over £100 million over the past decade. The Competition and Markets Authority (CMA) revealed its preliminary findings, accusing Concordia of exploiting its dominant market position to inflate the price of liothyronine, a critical drug for treating underactive thyroid conditions. The price surge was astronomical, with the cost of liothyronine skyrocketing by nearly 6,000% between 2007 and 2017. This drastic increase saw the NHS's expenditure on the drug balloon from approximately £600,000 in 2006 to a staggering £34 million in the past year alone.

Strategy seemed to be at the heart of Concordia's actions, as the company systematically raised the price per pack from £4.46 in 2007 to an eye-watering £258.19 by July 2017. The cost of a single pill jumped from 16p to £9.22, despite production costs remaining relatively stable over the same period. The CMA's investigation highlighted the stark disparity between the soaring prices and the unchanged manufacturing expenses, suggesting a deliberate move to maximize profits at the expense of public health funding. If found guilty, Concordia could face a hefty fine of up to 10% of its global annual turnover, underscoring the severity of the allegations.

Liothyronine tablets are essential for treating hypothyroidism, a condition affecting at least two in every 100 people and characterized by symptoms like depression, fatigue, and weight gain. For many patients, there are no viable alternatives to this medication, making Concordia's monopoly particularly troubling. Until recently, Concordia was the sole supplier of liothyronine in the UK, giving it unprecedented control over the market and pricing. This situation left the NHS and patients vulnerable to the company's pricing strategies, with no other options to turn to for this life-changing treatment.

However, a glimmer of hope emerged this summer when the UK firm Morningside Healthcare and Israel’s Teva were granted licences to supply liothyronine. This development introduced much-needed competition into the market, potentially easing the financial burden on the NHS and ensuring more affordable access to the drug for patients. The synthetic hormone T3, which liothyronine replicates, remains crucial for those who do not respond well to the cheaper alternative, levothyroxine. As the investigation continues, the healthcare community and patients alike await the outcome, hoping for justice and a resolution that prioritizes public health over profit margins."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']

deepseek-v3

"Concordia International, a Canadian pharmaceutical company, has been accused of overcharging the NHS by more than £100 million over the past decade for a critical thyroid medication, liothyronine. According to Britain’s Competition and Markets Authority (CMA), Concordia exploited its dominant market position to inflate the drug’s price by nearly 6,000% between 2007 and 2017. During this period, the NHS’s expenditure on liothyronine skyrocketed from approximately £600,000 in 2006 to over £34 million in 2022. The cost per pack surged from £4.46 in 2007 to £258.19 by July 2017, with the price of a single pill jumping from 16p to £9.22, despite production costs remaining stable. The CMA has warned that Concordia could face fines of up to 10% of its global annual turnover for this alleged abuse.

Strategy played a central role in Concordia’s actions, as the company leveraged its monopoly on liothyronine to impose exorbitant price hikes. Liothyronine, a synthetic version of the thyroid hormone T3, is a lifeline for patients with hypothyroidism who do not respond to the cheaper alternative, levothyroxine. With no other suppliers in the market until recently, Concordia held a near-exclusive grip on the drug, leaving the NHS with little choice but to pay the inflated prices. This exploitation of a vulnerable patient population has drawn widespread criticism, particularly as hypothyroidism affects at least two in 100 people and can lead to severe symptoms like depression, fatigue, and weight gain.

The situation began to shift earlier this year when the UK’s Morningside Healthcare and Israel’s Teva were granted licenses to supply liothyronine, breaking Concordia’s monopoly. This development has been hailed as a significant step toward reducing the financial burden on the NHS and ensuring patients have access to affordable treatment. However, the damage done over the past decade underscores the need for stricter oversight of pharmaceutical pricing practices. The CMA’s investigation highlights the critical importance of preventing companies from exploiting their market dominance at the expense of public health systems and patients.

Concordia’s case is a stark reminder of the ethical responsibilities pharmaceutical companies bear in delivering life-saving medications. While the company has yet to respond publicly to the CMA’s findings, the potential fines and reputational damage could have far-reaching consequences. For the NHS and patients, the entry of new suppliers offers hope for a more equitable and sustainable future. As the healthcare system continues to grapple with the financial pressures of rising drug costs, this case serves as a call to action for greater transparency and accountability in the pharmaceutical industry."

['startend:quotation' 'length_constraints:nth_paragraph_first_word']